Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Operating Expenses (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Other Operating Expenses for 4 consecutive years, with -$515000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses fell 156.22% to -$515000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $137000.0, a 94.33% decrease, with the full-year FY2024 number at $3.3 million, up 37.34% from a year prior.
  • Other Operating Expenses was -$515000.0 for Q3 2025 at Orchestra BioMed Holdings, down from -$36000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.2 million in Q3 2023 to a low of -$601000.0 in Q1 2022.
  • A 4-year average of $288466.7 and a median of $166000.0 in 2025 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 661.86% in 2023; the steepest drop was 532.05% in 2023.
  • Orchestra BioMed Holdings' Other Operating Expenses stood at $78000.0 in 2022, then tumbled by 532.05% to -$337000.0 in 2023, then skyrocketed by 254.9% to $522000.0 in 2024, then tumbled by 198.66% to -$515000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Other Operating Expenses are -$515000.0 (Q3 2025), -$36000.0 (Q2 2025), and $166000.0 (Q1 2025).